TY - JOUR T1 - Public/private partnerships, at what price? JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - e211 LP - e211 DO - 10.1136/annrheumdis-2020-217664 VL - 81 IS - 10 AU - Maarten Boers Y1 - 2022/10/01 UR - http://ard.bmj.com/content/81/10/e211.abstract N2 - From a scientific viewpoint, Huizenga and colleagues are completely right to endorse ‘disruption’ by public-private partnerships as a way to ‘accelerate innovation and enable translation of the rapidly expanding cellular and molecular understanding of disease pathogenesis into the development of new therapeutic agents’.1 However, one of their examples (monoclonal antibodies leading to the development of anti-tumour necrosis factor (TNF) treatment) highlights an aspect they did not … ER -